Allogenic Therapeutics Inc (NASDAQ: ALLO) has announced that preclinical trial results for its anti-BCMA CAR T cells have been published in the Cancer Research Communications journal. The findings indicated that the compound has a long-term effect on the compound.
According to a dermatologist and a study author in the research, Reuben Benjamin, hematological cancer is still incurable even though multiple myeloma now has a variety of treatments.
Unfortunately, many patients develop progressive disease. For this reason, they require accessible and effective treatments. This study could finally provide therapy for patients with hematological cancer.
The researchers retrieved bone marrow cells from young donors
The study showed that patients could potentially benefit from CAR T treatment extracted from young people through autologous approaches where scientists genetically engineer T cells from the patient to attack cancer cells.
Benjamin points out that healthy donors have more and healthier T cells. Their T cells also had a better anti-cancer destroying capability, and researchers could administer them quickly. BCMA also has broad expression and higher specificity; thus, doctors targeted it for multiple myeloma.
How researchers conducted the experiment
For the study, researchers generated anti-BCMA T cells from patients with multiple myeloma and young, healthy people. The patients with multiple myeloma had a median age of 61 years. Researchers compared the cytotoxic activity, fitness, and profile of the two groups.
When they examined the results, they found that young donors had more T cells and a higher ratio of CD4 to CD8 T cells. They also found that the anti-BCMA CAR T cells from healthy patients killed myeloma cells more effectively.
Allogene’s Chief Medical Officer, Rafael G Amado, states these results support the company’s intentions to develop anti-BCMA allogeneic CAR T cells for multiple myeloma patients. This move would help the company treat a disease with high unmet needs.
Allogene Therapeutics is a biotechnology company that focuses on developing groundbreaking treatments for cancer. It is now working to produce CAR T cell therapies to reduce the wait time when creating the treatment. This would enable patients to receive therapies reliably when needed. The company is working with a qualified team with expertise in allogeneic products to meet its goals.
The company has its primary operations in San Francisco.
